Olaparib plus abiraterone could be a new first-line treatment option for mCRPC

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of MS

MEET THE SENIOR TEAM

Lynda Williams

medwireNews Deputy Bureau Chief

Related Showcases

view all

Neurology

Unrestricted oral feedings reported by caregivers and affected persons across severity of…

Conference Coverage & Reporting

Neurology

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

Conference Coverage & Reporting

Neurology

Nusinersen treatment may improve aerobic capacity in adult SMA patients

Conference Coverage & Reporting

Neurology

Treatment linked to continued stabilization of motor function in adults with SMA

Conference Coverage & Reporting

Neurology

Study identifies miRNAs upregulated in SMA

Conference Coverage & Reporting

Neurology

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of…

Conference Coverage & Reporting

Building relationships through trusted content for healthcare professionals

A global leader in medical content